Please login to the form below

Not currently logged in
Email:
Password:

pembrolizumab

This page shows the latest pembrolizumab news and features for those working in and with pharma, biotech and healthcare.

Roche gets FDA nod for Tecentriq in small cell lung cancer

Roche gets FDA nod for Tecentriq in small cell lung cancer

without competition from other checkpoint inhibitors, particularly Merck &Co/MSD’s PD-1 inhibitor Keytruda (pembrolizumab) which is dominating the NSCLC category.

Latest news

More from news
Approximately 24 fully matching, plus 246 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H).

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Last year, the FDA approved Merck’s Keytruda (pembrolizumab) as a first-line agent alongside chemotherapy for metastatic NSCLC on data showing the chance of cancer progression was cut in half.

  • Deal Watch January 2017 Deal Watch January 2017

    patent dispute over Keytruda (pembrolizumab) therefore avoiding a court appearance scheduled for later in the year. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics